Moreover, the 36-month beta value for VRDN is 1.35. Analysts have varying opinions on the stock, with 10 analysts rating it as a “buy,” 5 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for VRDN is 70.50M and currently, short sellers hold a 16.50% of that float. On January 31, 2025, VRDN’s average trading volume was 1.39M shares.
VRDN) stock’s latest price update
Viridian Therapeutics Inc (NASDAQ: VRDN)’s stock price has increased by 3.35 compared to its previous closing price of 19.43. However, the company has seen a 7.04% increase in its stock price over the last five trading sessions. seekingalpha.com reported 2024-12-19 that Company reported positive phase 3 THRIVE-2 study results using veligrotug in treating chronic thyroid eye disease patients, positioning it to file a BLA in the 2nd half 2025. The company is developing VRDN-003, an improved subcutaneous version of veligrotug for TED patients, with phase 3 REVEAL-1 and REVEAL-2 topline data expected in early 2026. Promising pipeline candidates include FcRn inhibitors VRDN-006 and bispecific VRDN-008, targeting IgG-mediated autoimmune disorders with potentially superior efficacy.
VRDN’s Market Performance
VRDN’s stock has risen by 7.04% in the past week, with a monthly rise of 3.24% and a quarterly drop of -13.75%. The volatility ratio for the week is 5.52% while the volatility levels for the last 30 days are 5.28% for Viridian Therapeutics Inc The simple moving average for the past 20 days is 6.73% for VRDN’s stock, with a 14.67% simple moving average for the past 200 days.
Analysts’ Opinion of VRDN
Many brokerage firms have already submitted their reports for VRDN stocks, with Wells Fargo repeating the rating for VRDN by listing it as a “Equal Weight.” The predicted price for VRDN in the upcoming period, according to Wells Fargo is $27 based on the research report published on December 19, 2024 of the previous year 2024.
Needham gave a rating of “Buy” to VRDN, setting the target price at $38 in the report published on September 11th of the previous year.
VRDN Trading at 3.09% from the 50-Day Moving Average
After a stumble in the market that brought VRDN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -26.18% of loss for the given period.
Volatility was left at 5.28%, however, over the last 30 days, the volatility rate increased by 5.52%, as shares surge +2.76% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -7.21% lower at present.
During the last 5 trading sessions, VRDN rose by +7.04%, which changed the moving average for the period of 200-days by +26.37% in comparison to the 20-day moving average, which settled at $18.81. In addition, Viridian Therapeutics Inc saw 4.75% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VRDN starting from Beetham Thomas W., who purchase 5,000 shares at the price of $23.41 back on Sep 27 ’24. After this action, Beetham Thomas W. now owns 6,000 shares of Viridian Therapeutics Inc, valued at $117,050 using the latest closing price.
Mahoney Stephen F., the President and CEO of Viridian Therapeutics Inc, purchase 21,400 shares at $23.33 during a trade that took place back on Sep 27 ’24, which means that Mahoney Stephen F. is holding 21,400 shares at $499,262 based on the most recent closing price.
Stock Fundamentals for VRDN
Current profitability levels for the company are sitting at:
- -937.23 for the present operating margin
- -20.48 for the gross margin
The net margin for Viridian Therapeutics Inc stands at -851.27. The total capital return value is set at -0.39. Equity return is now at value -51.88, with -46.71 for asset returns.
Based on Viridian Therapeutics Inc (VRDN), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -9.33. The debt to equity ratio resting at 0.03. The interest coverage ratio of the stock is -91.19.
Currently, EBITDA for the company is -234.56 million with net debt to EBITDA at 0.71. When we switch over and look at the enterprise to sales, we see a ratio of 4673.46. The receivables turnover for the company is 21.57for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 18.55.
Conclusion
To wrap up, the performance of Viridian Therapeutics Inc (VRDN) has been mixed in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
